FRED requires a protein to be docked into, a definition of a region in that protein in which the docking will take place and a multi-conformer database of molecules to be docked. The most common format for database file(s) is a multi-conformer OEBinary file created by OpenEye’s OMEGA application, however, this file can be one of several 3D formats. These formats include SDF, MOL2 and PDB. FRED determines the database file format from the file extension, .sdf or .mol for SDF, .mol2 for MOL2, .pdb or .ent for PDB. Gzip compressed files of these same formats are allowed as well. FRED will interpret infile.sdf.gz as a gzip’ed SDF file.
Even though all these formats are supported, using SDF, PDB or MOL2 can result in a loss of speed due to the I/O penalty of these formats.
To encapsulate all of the receptor information, the receptor molecule file must be in .oeb or .oeb.gz format.
To dock a set of ligands into the receptor 2IKO_receptor.oeb.gz:
> fred -receptor 2IKO_receptor.oeb.gz -dbase all.oeb.gz
If you have a multi-processor machine, you can harness the extra computing power by using OpenMPI. To re-run the job on a host with 4 processors, you enter the following:
> fred -mpi_np 4 -receptor 2IKO_receptor.oeb.gz -dbase all.oeb.gz -prefix 2IKO_fred
The output from the docking runs may be viewed in VIDA, as depicted in figure 2IKO FRED Docked.
In addition to analyzing and visualizing the output from a docking run in VIDA, a summary PDF report can be generated using DockingReport.
> docking_report -docked_poses 2IKO_fred_docked.oeb.gz \ -receptor 2IKO_receptor.oeb.gz -report_file 2IKO_fred_docked_report.pdf
The result of running the above command is depicted in figure 2IKO FRED Docking Report.
The PDF report includes a 2D depiction of each molecule, a breakdown of the docking score components by atom, a comparison of the molecule’s score compared to the other docked molecules, and a ‘Residue Fingerprint’ which highlights which residues in the receptor site the ligand is interacting with. Greyed out residues are residues in the site that other ligands interact with, but the current ligand does not.